(R)-benzyl 2-methylpiperidine-1-carboxylate | 1346681-73-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-benzyl 2-methylpiperidine-1-carboxylate
• 英文别名: benzyl (R)-2-methylpiperidine-1-carboxylate；benzyl (2R)-2-methylpiperidine-1-carboxylate
• CAS: 1346681-73-9
• 化学式: C₁₄H₁₉NO₂
• 分子量: 233.31
• InChiKey: LVYFPZCDWNZWNY-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (1E)-4-羟基-1-三甲苯基-4-甲基戊-1-烯-3-酮 、 氯甲酸苄酯 、 2-甲基哌啶 在 2-(2,4,6-trimethyl-phenyl)-2,5,6,7-tetrahydro-pyrrolo[2,1-c] [1,2,4]triazol-4-ylium perchlorate 、 (4aR,9aS)-4-hydroxy-4,4a,9,9a-tetrahydroindeno[2,1-b][1,4]oxazin-3(2H)-one 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 生成 (R)-benzyl 2-methylpiperidine-1-carboxylate 、 (S)-benzyl 2-methylpiperidine-1-carboxylate 、 (R)-1-(3-mesitylpropanoyl)-2-methyl piperidine 、 (S)-1-(3-mesitylpropanoyl)-2-methyl piperidine
  参考文献：
  名称：

  环状仲胺的催化动力学拆分

  摘要：

  外消旋环胺的催化拆分是通过对映选择性酰胺化反应实现的，该反应具有非手性 N-杂环卡宾催化剂和新型手性异羟肟酸助催化剂协同作用。反应在室温下进行，不产生非挥发性副产物，并通过水萃取提供富含对映体的胺。

  DOI：

  10.1021/ja209472h

文献信息

• [EN] HALO AND TRIFLUOROMETHYL SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE SUBSTITUÉS PAR DES GROUPES HALO ET TRIFLUOROMÉTHYLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014176146A1

  公开（公告）日：2014-10-30

  The present invention is directed to halo and trifluoromethyl substituted compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及卤代和三氟甲基取代化合物，其为促进醒觉素受体拮抗剂。本发明还涉及上述化合物在潜在的神经和精神障碍和疾病的治疗或预防中的应用，其中醒觉素受体参与其中。本发明还涉及包含这些化合物的制药组合物。本发明还涉及这些制药组合物在预防或治疗醒觉素受体参与的这些疾病中的应用。
• [EN] KINETIC RESOLUTION OF CHIRAL AMINES<br/>[FR] RÉSOLUTION CINÉTIQUE D'AMINES CHIRALES
  申请人：ETH ZUERICH

  公开号：WO2013007371A2

  公开（公告）日：2013-01-17

  The present invention refers to a method for the kinetic resolution of a chiral primary or secondary amine by treating the amine with a chiral, hydroxamic acid derived reagent of the formula (I). These chiral reagents are particularly useful for the kinetic resolution of cyclic amines and may be generated in situ in the presence of an N-heterocyclic carbene, thus allowing for a catalytic reaction.
• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：PHARMACYCLICS LLC

  公开号：WO2016196776A2

  公开（公告）日：2016-12-08

  Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are describeded, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.